Department of Pharmacology Archives
Vanderbilt study suggests way to prevent rare lung disease
Nov. 15, 2018—Research by Vanderbilt scientists suggests that it may be possible to prevent or even reverse pulmonary arterial hypertension, a rare, progressive disease characterized by narrowing of and high blood pressure in the small arteries of the lungs.
Four researchers receive Young Investigator Grants
Nov. 15, 2018—Four Vanderbilt University researchers are among 200 recipients of this year’s Young Investigator Grants awarded by the Brain & Behavior Research Foundation to support “innovative ideas for groundbreaking neurobiological research.”
Novel methods to treat glaucoma
Nov. 8, 2018—Increasing a certain signaling molecule prevents the degeneration of retinal cells that are lost in glaucoma, suggesting a new way to treat this disease.
Cytokine-cognition connection
Oct. 1, 2018—Targeting the immune system may provide a new avenue for therapeutic intervention in psychiatric diseases characterized by motivational and cognitive deficits.
Innovative strategies crucial in opioid epidemic response
Sep. 27, 2018—Reining in the nation’s opioid epidemic will require diverse and innovative strategies ranging from drug discovery to “policy translation,” according to speakers at a recent Vanderbilt Faculty Cutting-edge Discovery Lecture.
Student-invited Pharmacology Forum
Jul. 19, 2018—Graduate students in the Department of Pharmacology hosted the 27th annual Joel G. Hardman Student-Invited Pharmacology Forum and presented the annual “Teacher of the Year” award to Joshua Fessel, MD, PhD.
Vanderbilt licenses compound to Nashville’s Appello to advance Parkinson’s therapies
Jul. 12, 2018—Vanderbilt University has signed a licensing agreement with Nashville-based start-up Appello Pharmaceuticals, Inc. to advance novel compounds developed by researchers in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) for the treatment of Parkinson’s disease.
Scavengers “protect” HDL
Jun. 29, 2018—Jun. 29, 2018—Lipid molecules that bind to HDL can modify its function — and blocking that modification can protect HDL and potentially lower the risk of atherosclerosis and heart disease.
Roden’s circulatory diseases research honored
Jun. 21, 2018—Jun. 21, 2018—Vanderbilt University’s Dan Roden, MD, internationally known for his contributions to understanding how genetic variation affects drug response, has been named a recipient of the 2018 Louis and Artur Lucian Award for Research in Circulatory Diseases by McGill University in Montreal, Canada.
Roden’s circulatory diseases research honored
Jun. 21, 2018—Vanderbilt University’s Dan Roden, MD, internationally known for his contributions to understanding how genetic variation affects drug response, has been named a recipient of the 2018 Louis and Artur Lucian Award for Research in Circulatory Diseases by McGill University in Montreal, Canada.
Opioid epidemic focus of June 27 Student-Invited Pharmacology Forum
Jun. 14, 2018—“America’s Opioid Epidemic” is the theme of the 27th annual Joel G. Hardman Student-Invited Pharmacology Forum, beginning at 9 a.m. Wednesday, June 27, in the Vanderbilt Student Life Center.
Enzyme protects against obesity-related heart disease
Jun. 7, 2018—Vanderbilt scientists have discovered that a certain enzyme plays a crucial role in preventing obesity-related cardiac dysfunction.